Read the December 2018 Digital Edition
The December 2018 Digital Edition features the inaugural class of Best Places to Work, Outlook 2019, and more.
The December 2018 Digital Edition features the inaugural class of Best Places to Work, Outlook 2019, and more.
What existing and future trends do marketers in the rare diseases area need to be mindful of to optimize their efforts?
Investment in digital health companies shattered all existing records during 2018 — and startups in the behavioral health area snagged a good deal of it.
Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.
Now that the political climate lends itself to action on drug pricing, the days of pharma nirvana may be coming to an end. Here’s a look at the policy considerations likely to vex the industry in the year ahead.
Amanda Hartzmark is director of business development and analysis at AbelsonTaylor.
Robin Davenport, EVP, executive creative director at Sudler, believes marketers and communicators must take an active role in creating a healthier future.
Not surprisingly, transparency and personalization top the list of patient priorities.
Are today’s developmental drugs tomorrow’s blockbusters? We survey what’s ahead for top candidates in six therapeutic categories.
Maintaining and upping their internal fun quotient can help healthcare agencies cultivate people who will carry on the great legacy of marketing firms as the quintessential partners.